However, this doesn't mean you can't have strong opinions about certain investments. I'm quite confident that some stocks will be winners over the long run. Here are my three highest-conviction growth ...

Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...

ReverseLogix, a provider of end-to-end returns management systems, today announced its Founder & CEO, Gaurav Saran, has been honored with a placement on The Software Report's Top 50 Software CEOs of ...

Klick Health is taking a fellow life-sci-centric agency under its wing. | Klick Health is taking a fellow life-sci-centric ...

“It’s just 26 years since we first learnt to culture human stem cells in ... early results from a trial run by the drug company Vertex Pharmaceuticals based in Boston, Massachusetts, have ...

These offbeat classics, picked by people working in key sectors, can act as spiritual guidebooks, revealing the subtler nuances in corporate culture or the artistry of the day-to-day. Crucially, they ...

The announcement is remarkable because Enzyvant is the first company to receive ... Roivant's partners include Merck, Takeda Pharmaceuticals, GlaxoSmithKline, Eisai, Vertex Pharmaceuticals ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...